Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The exocrine pancreatic insufficiency treatment market was valued at USD 4.22 billion in 2023, driven by the increasing cases of cystic fibrosis, which commonly develop EPI due to thickened secretions that obstruct the pancreatic ducts across the 8 major markets. The market is expected to grow at a CAGR of 8.27% during the forecast period of 2024-2032, with the values likely to reach USD 8.63 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Exocrine pancreatic insufficiency (EPI) is a condition characterized by the inability of the pancreas to produce enough digestive enzymes to properly digest food. The treatment includes PERT, which involves taking pancreatic enzyme supplements with meals and snacks to replace the deficient enzymes. The enzyme supplements typically contain lipase, protease, and amylase to aid in the digestion of fats, proteins, and carbohydrates.
EPI is primarily caused by conditions that affect pancreatic function, such as chronic pancreatitis, cystic fibrosis, pancreatic cancer, and pancreatic surgery. The prevalence of these underlying conditions contributes to the growing demand for EPI treatment market.
The pharmaceutical companies are focusing on developing advanced formulations of pancreatic enzymes to improve stability, efficacy, and patient compliance. These innovations aim to optimize treatment outcomes and enhance patient satisfaction, which is expected to drive the market growth.
Increasing Incidence and Prevalence of Underlying Conditions
Chronic pancreatitis is a significant cause of EPI, which is increasingly diagnosed due to rising cases linked to alcohol abuse, obesity, and other factors. This genetic condition affects pancreatic function, leading to EPI in a substantial number of patients. According to an article published by NCB I, chronic pancreatitis is the most common pancreatic disease associated with EPI.
Other conditions like pancreatic cancer and surgical interventions on the pancreas can impair its ability to produce digestive enzymes, necessitating EPI treatment. According to an article published by NCB I, pancreatic surgery alters digestive anatomy, the correct mixing of food, bile, and pancreatic enzymes and reduces the pancreatic volume. Different procedures are associated with different degrees of EPI. The growing number of individuals diagnosed with chronic pancreatitis directly expands the pool of patients at risk of developing EPI, thereby increasing the demand for its treatment market.
Technological Advancements in Treatment Options is Expected to Propel Exocrine Pancreatic Insufficiency Treatment Market Demand
The technological advancements in treatment options play a crucial role in driving the growth and development of the treatment market. The technological innovations enable the development of more effective formulations of pancreatic enzymes, including lipase, protease, and amylase. These formulations are designed to better mimic natural pancreatic enzyme activity, thereby improving digestion and nutrient absorption in patients with EPI. Pancreatic Enzyme Replacement Therapy (PERT) remains the mainstay of EPI treatment, with ongoing advancements in enzyme formulations, delivery systems, and dosing regimens to enhance efficacy and patient compliance.
The advancement in treatment includes other alternative therapies, exploration of adjunctive therapies, such as proton pump inhibitors (PPIs), dietary modifications, and nutritional supplements, provides additional treatment options tailored to patient needs. This innovation leads to increase in market demand.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
Key Trends | Impact |
Advancements in Enzyme Replacement Therapy | There is ongoing research and development aimed at enhancing the efficacy, stability, and bioavailability of pancreatic enzyme replacement therapy (PERT). The innovations include formulations with optimized enzyme ratios, enteric-coated tablets for improved delivery, and microencapsulation technologies to protect enzymes from degradation. These advancements are expected to drive the market growth. |
Exploration of Novel Therapies | The ongoing research efforts are focused on exploring novel therapeutic approaches beyond traditional enzyme replacement, including enzyme enhancers, pancreatic duct clearance agents, and targeted therapies addressing underlying disease mechanisms. |
Personalized Medicine Approach | The increasing use of genetic testing helps identify specific mutations (e.g., CFTR mutations in cystic fibrosis-related EPI) that influence treatment responses. This allows for personalized treatment plans tailored to individual genetic profiles, optimizing therapy effectiveness and patient outcomes. This is expected to drive market growth. |
Market Breakup by Treatment
Market Breakup by Indication
Market Breakup by End User
Market Breakup by Region
Market Segmentation Based on Treatment is Anticipated to Witness Substantial Growth
By treatment, the market is segmented into pancreatic enzyme replacement therapy (PERT), nutritional therapy (dietary supplements) and others. The pancreatic enzyme replacement therapy (PERT) segment is expected to dominate the market because it is the most recommended treatment. It helps in managing EPI symptoms by replacing the deficient pancreatic enzymes (lipase, protease, amylase) required for proper digestion of fats, proteins, and carbohydrates.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Regionally, the market report offers an insight into the United States, EU-4 and the United Kingdom, Germany, France, Italy, Spain, United Kingdom, Japan, and India. The United States, having a robust healthcare infrastructure and a strong presence of prominent pharmaceutical companies, is estimated to hold a high market value. The robust research and development activities in pharmaceutical and biotechnology sectors, leading to continuous advancements in pancreatic enzyme replacement therapy (PERT) formulations, driving the regional demand.
Germany holds a high exocrine pancreatic insufficiency treatment market value as the region boasts a well-developed healthcare system with robust diagnostic capabilities and access to specialized care, facilitating early detection and management of EPI.
Additionally, Japan is expected to witness substantial market growth as the region has made significant progress in raising awareness among healthcare providers about gastrointestinal disorders, including EPI. This has led to improved diagnosis and management of the condition and thus driving the market demand.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, fundings and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
AbbVie Inc.
AbbVie Inc., a prominent pharmaceutical company, has been involved in the treatment of exocrine pancreatic insufficiency (EPI) through its development and marketing of pancreatic enzyme replacement therapy (PERT) products.
Johnson & Johnson Services, Inc.
Johnson & Johnson Services, Inc., as a global pharmaceutical company focuses on several therapeutic areas such as pharmaceuticals, generics, eye care, and oncology, among others, including EPI.
Other key players in the market include Nordmark Arzneimittel GmbH and Co. KG, Digestive Care, Inc., Cilian AG, Chiesi Farmaceutici S.p.A., Anthera Pharmaceuticals, Inc., and Aptalis Pharma Inc. among others.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Treatment |
|
Breakup by Indication |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
Share